Close Menu
  • Home
  • AI
  • Education
  • Entertainment
  • Food Health
  • Health
  • Sports
  • Tech
  • Well Being

Subscribe to Updates

Subscribe to our newsletter and never miss our latest news

Subscribe my Newsletter for New Posts & tips Let's stay updated!

What's Hot

His AI Startup Has a Literal Moat: a Castle for an Office

July 4, 2026

The only AI glossary you’ll need this year

July 3, 2026

Samsung S90H 4K TV Review: a Midrange OLED Fit for Any Room

July 3, 2026
Facebook X (Twitter) Instagram
  • Home
  • About Us
  • Advertise With Us
  • Contact us
  • DMCA
  • Privacy Policy
  • Terms & Conditions
Facebook X (Twitter) Instagram
IQ Times Media – Smart News for a Smarter YouIQ Times Media – Smart News for a Smarter You
  • Home
  • AI
  • Education
  • Entertainment
  • Food Health
  • Health
  • Sports
  • Tech
  • Well Being
IQ Times Media – Smart News for a Smarter YouIQ Times Media – Smart News for a Smarter You
Home » Moderna halts development of birth defect vaccine after trial setback
Health

Moderna halts development of birth defect vaccine after trial setback

IQ TIMES MEDIABy IQ TIMES MEDIAJuly 1, 2007No Comments2 Mins Read
Facebook Twitter Pinterest LinkedIn Tumblr Email
Share
Facebook Twitter LinkedIn Pinterest Email


By Kamal Choudhury

(Reuters) -Moderna said on Wednesday it would stop developing its experimental vaccine to prevent cytomegalovirus, a virus that can cause birth defects, after it failed to meet the main goal of a late-stage trial.

Shares of the drugmaker were down over 5% in extended trading following the news.

The late-stage trial tested the vaccine, mRNA-1647, in about 7,500 women aged 16 to 40. The shot showed efficacy ranging between 6% and 23%, depending on how the cases were defined, which was below Moderna’s target.

Cytomegalovirus is a common virus that usually causes mild illness. However, if passed from mother to baby during pregnancy, it can lead to congenital CMV, a condition that may cause birth defects or long-term health problems.

There is currently no approved vaccine to prevent congenital CMV.

Nearly one in three U.S. children is infected with cytomegalovirus by age five and about one in 200 babies is born with the congenital form, according to the CDC.

“We are clearly disappointed by the failure to prevent primary infection because it means there is still no vaccine for the prevention of congenital CMV despite the many decades of work by the field,” said Moderna President Stephen Hoge, MD.

“Like most investors, we saw CMV failure a matter of when, not if,” said analysts at Leerink Partners, citing slow trial progress, a failed interim analysis and the management’s earlier signals about changing the study’s evaluation criteria.

TD Cowen analyst Tyler Van Buren said they had hoped Moderna’s vaccine would outperform Sanofi’s earlier CMV candidate, which showed around 50% efficacy before being discontinued.

Moderna said it will continue to evaluate the vaccine in a separate mid-stage trial in bone marrow transplant patients, where CMV reactivation can cause severe disease.

The vaccine was generally well-tolerated and no safety concerns were flagged, it said.

The company does not expect the trial failure to affect its financial outlook for 2025 or its goal to break even by 2028.

(Reporting by Kamal Choudhury in Bengaluru; Editing by Shreya Biswas and Maju Samuel)



Source link

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
IQ TIMES MEDIA
  • Website

Related Posts

What an expert on the gut microbiome eats in a day

March 26, 2026

Wegovy maker Novo sharpens consumer focus with board role for Mars CEO

March 26, 2026

CDC report finds US smoking rate continues to plummet as vape use rises

March 26, 2026
Add A Comment
Leave A Reply Cancel Reply

Editors Picks

Trump Accounts launch on USA’s 250th birthday. Here’s how to sign up

July 2, 2026

World Cup may mint more soccer fans among US kids

July 1, 2026

Could feds’ changes put more people with disabilities in institutions?

July 1, 2026

Judge strikes down Trump rules on public service student loan forgiveness

June 30, 2026
Education

Trump Accounts launch on USA’s 250th birthday. Here’s how to sign up

By IQ TIMES MEDIAJuly 2, 20260

WASHINGTON (AP) — On Saturday, President Donald Trump’s administration plans to launch Trump Accounts, tying…

World Cup may mint more soccer fans among US kids

July 1, 2026

Could feds’ changes put more people with disabilities in institutions?

July 1, 2026

Judge strikes down Trump rules on public service student loan forgiveness

June 30, 2026
IQ Times Media – Smart News for a Smarter You
Facebook X (Twitter) Instagram Pinterest Vimeo YouTube
  • Home
  • About Us
  • Advertise With Us
  • Contact us
  • DMCA
  • Privacy Policy
  • Terms & Conditions
© 2026 iqtimes. Designed by iqtimes.

Type above and press Enter to search. Press Esc to cancel.